Background. Novel antibiotics will not be available to combat the threat of MBLs until 2021. One strategy to overcome MBLs is to combine CAZ-AVI + ATM. ATM is not hydrolysed by MBLs and AVI offers protection for ATM and CAZ vs. ESBLs and AmpCs. The combination also offers a theoretical advantage to inactivating multiple PBPs by using dual β-lactam therapy. Our objective was to define optimal dosing profiles for clinical use of ATM to add to CAZ-AVI in the hollow fiber infection model (HFIM).
Background. Oral fosfomycin is indicated for uncomplicated urinary tract infections with activity against MDR-uropathogens. Despite off-label use of giving three doses every 2-3 days, limited supporting data are available. We performed pharmacodynamic profiling using a dynamic bladder infection in vitro model to assess adequacy of repeat doses of fosfomycin.
Methods. A bladder infection in vitro model simulating urinary fosfomycin concentrations after 3 g (equiv.) oral doses was used with Mueller-Hinton broth (MHB) with 25 mg/L glucose-6-phosphate. Fosfomycin exposures were validated by LC-MS/ MS measurements. Pharmacodynamic response of 16 clinical Enterobacteriaceae isolates were examined (eight E. coli, four E. cloacae, four K. pneumoniae; agar dilution MIC 0.25-64 mg/L) following three doses of fosfomycin given every 72, 48 or 24 hours, compared with single dose therapy. Pathogen kill and resistance was assessed by quantitative cultures on drug-free and fosfomycin-containing Mueller-Hinton agar (MHA +64 mg/L, +512 mg/L).
Results. Fosfomycin exposure following single and multiple doses were accurately reproduced (mean deviation from target 5.0 ± 3.4%, max 11.8%) with minimal variability (mean relative SD 2.7 ± 1.7%, max 8.8%). Fosfomycin high-level heteroresistance was detected prior to drug exposure in 8/16 isolates (proportion 0.00002-0.001% of total population). All isolates with high-level heteroresistance regrew following single dose fosfomycin. Following three doses given every 72 hours, one additional K. pneumoniae isolate was killed. All other isolates regrew with amplification of HLR subpopulation (median proportion: 71.4%, IQR 57.5-100%). Despite dosing 48 and 24 hourly, the same isolates regrew, although HLR subpopulation amplification was reduced (48 hours dosing: 32.0%, IQR 0.005-83.3%; 24 hours dosing: 0.3%, IQR 0.0004-81.3%).
Conclusion. Dynamic in vitro modeling of multiple doses of oral fosfomycin fails to additionally suppress regrowth in the majority of isolates compared with single dose therapy. Baseline high-level heteroresistance is an important predictor for regrowth. These results suggest that giving multiple doses of fosfomycin is not necessarily better than standard single dose therapy. Earlier timing of repeat doses may help suppress the emergence of resistance.
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Phase I Study to Evaluate the Safety and Pharmacokinetics (PK) of Single and Multiple Ascending Doses (SAD/MAD) of Intravenous (IV) Minocycline in Healthy Adult Subjects
Methods. This was a randomized, double blind, placebo-controlled, SAD/MAD study of 6 doses (100-600 mg) of IV minocycline. Healthy adult subjects received a single dose of minocycline or placebo on Day 1, and 15 doses BID starting on Day 4. Safety was assessed throughout the study. Serial blood and urine samples were collected for PK assessment.
Results. Sixty-nine healthy subjects were randomized, 49 were included in the PK analysis. No serious adverse events (AEs) occurred; 55 subjects (79.9%) reported study drug-related AEs; dizziness 40 (58.0%) and nausea 34 (49.3%) were the most common. All related AEs were mild except for seven subjects with moderate nausea and/or dizziness. Dosing in the 400 mg cohort was discontinued due to AEs, therefore MAD escalation was stopped. Subsequent cohorts were escalated for SAD and loading dose only. 
